What if a tiny, non-hallucinogenic dose of LSD could transform the way we treat depression?

In this episode of Vital Stuff, Dr. Gail Lebovic talks with entrepreneur and investor Justin Hanka about his pioneering work at MindBio, the first company in the world approved to run take-home clinical trials of microdosing LSD.

Justin shares how microdosing is showing remarkable results in treating depression, why New Zealand is leading the global charge, and how unexpected discoveries - like using voice recognition to detect intoxication - could open up an entirely new frontier in health innovation.

You’ll learn:

• Why antidepressants fail so many patients

• How microdosing LSD works (without hallucinations)

• The link between psychedelics, neurogenesis & brain health

• Potential applications for dementia, Alzheimer’s & longevity

• How AI voice analytics may change the way we measure health

  
  

  
  

About Justin Hanka

Justin is an Australian entrepreneur and co-founder of MindBio, a biotech company pushing the boundaries of mental health treatment through psychedelic research. With a career spanning wellness, finance, and biotech, Justin is building science-driven solutions to some of the world’s toughest health challenges.

🎧 New episodes of Vital Stuff drop every other Thursday.
Follow Dr. Gail on LinkedIn: linkedin.com/in/gaillebovic